Roivant Provides Update on Graves’ Disease Development Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Roivant Sciences (ROIV) PT Raised to $12.50 at BofA Securities
September 11, 2024 5:18 AM EDTBofA Securities analyst Chi Fong raised the price target on Roivant Sciences (NASDAQ: ROIV) to $12.50 (from $12.00) while maintaining a Neutral rating.
The analyst comments "Roivant (ROIV) disclosed a new Ph2-ready program, mosliciguat, for interstitial lung disease (PH-ILD). We think the Ph1... More
